EN DE
Watch Zenith Healthcare Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zenith Healthcare Limited (530665) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Zenith Healthcare Limited stock ₹1.88, price ₹3.20, that is 41.3% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN

ZH Zenith Healthcare Limited logo Thin data Nov 17, 2026

Zenith Healthcare Limited

530665 · BSE

Far too expensive (fair value 41% below the price) and falling price, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +52% vs. a year ago. 
Quality 52/100 
Thin margins · 6.9% net margin (TTM) 
Fair value ₹1.88 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −5.2 %/yr in INR) 
Negative free cash flow 
Trails peers (4/13) 
Narrow moat 38/100 · thin data
Thin data 
Watch Zenith Healthcare Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹11.20 ₹2.42 Fair Value ₹1.88 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range ₹2.42 – ₹11.20 · fair‑value band ₹1.88 – ₹2.82 · the ₹3.20 price screens above the ₹1.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 17, 2026.

Follow Zenith Healthcare in your weekly email

Every Wednesday you see whether Zenith Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zenith Healthcare Limited manufactures, sells, and exports pharmaceutical formulations in India. The company offers products in the form of tablets, capsules, oral liquids, and injections in various therapeutic areas. It also engages in the contract manufacturing of various dosage forms.

Show moreShow less

The company also supplies medicines to Cambodia, Myanmar, Papa New Guinea, Sri Lanka, Kenya, Nigeria, Gambia, Zambia, Namibia, Botswana, Armenia, Georgia, Uzbekistan, Paraguay, Bolivia, Venezuela, Guatemala, Barbados, Jamaica, Bahamas, Yemen, and Turkey.

Zenith Healthcare Limited was founded in 1994 and is based in Ahmedabad, India.

Stock analysis

Zenith Healthcare Limited (530665) currently trades at ₹3.20, while our model-based Fair Value estimate is ₹1.88, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹1.88 per share, and 3 of the 7 models we run sit above the ₹3.20 price.

Bear case: the Earnings-Based group reads lowest at ₹1.88, and 4 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹1.88 (bear) to ₹2.82 (bull), the price of ₹3.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Zenith Healthcare Limited reported revenue of ₹105M in FY2026 versus ₹224M in FY2022, a compound −17.2%/yr. Reported net income was ₹51.0K in FY2026, compounding −64.2%/yr from FY2022.

Key figures

Market cap ₹247M (≈ $2.6M) Micro · P/E ratio 30.1 · P/S ratio 1.69 · EPS (TTM) ₹0.1700 · Net margin 6.9% · Return on equity 15.7% · Return on assets (EBIT) −1.2% (5-year average) · Operating margin 6.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −41%, 530665 screens richer than that median.

Fair Value models

Bear ₹1.88 Fair Value ₹1.88 Bull ₹2.82
Price ₹3.20 · Downside -41.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹0.1076 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹62.04 ₹67.68 ₹78.02 71
Growth-Adj P/E ₹0.9400 ₹1.88 ₹1.88 68
Graham-Dodd ₹0.9400 ₹1.88 ₹1.88 67
All 8 models by family
Earnings-Based
Graham-Dodd ₹0.9400 ₹1.88 ₹1.88 67
PEG = 1.0 n/a n/a ₹0.9400 54
Multiples
P/E Multiple ₹1.88 ₹1.88 ₹2.82 63
P/S Multiple ₹0.9400 ₹1.88 ₹1.88 58
P/B Multiple ₹438.04 ₹584.68 ₹730.38 55
Asset-Based
NCAV (Graham) ₹45.12 ₹67.68 ₹84.60 55
Economic Profit
Residual Income ₹62.04 ₹67.68 ₹78.02 71
Growth Earnings
Growth-Adj P/E ₹0.9400 ₹1.88 ₹1.88 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 42
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 27
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2021 (pandemic). Over 10 years: +11.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−59.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−59.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → −4%

530665 screens overvalued: fair value 41% below the price. Compare with Merck KGaA →

Compare Zenith Healthcare Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −41.3% · Below median
Profitability
Return on equity (12 months) 15.7% · Top 25%
Return on assets 0.1% · Below median
Net margin (12 months) 6.9% · Below median
Operating margin (12 months) 6.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 51.6% · Top 25%
Dividend yield (12 months) 0.0% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 30.1× · Pricier than median
P/B 3.32× · Priciest 25%
P/S (12 months) 1.69× · Cheaper than median
EV/EBITDA 21.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)63 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs 530665
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs 530665
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs 530665
Haleon plc HLN $9.20 $8.47 −8% vs 530665
Merck KGaA MRK €149.70 €108.83 −27% vs 530665
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs 530665
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs 530665
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs 530665
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs 530665
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs 530665

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zenith Healthcare Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zenith Healthcare Limited Fair Value". https://www.fairvalue-calculator.com/stock/530665

Frequently asked questions

Is Zenith Healthcare Limited (530665) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of ₹1.88 versus a price of ₹3.20, about 41% lower (overvalued).
What is the fair value of 530665?
Our model-based fair value for Zenith Healthcare Limited is ₹1.88 (as of Nov 17, 2026), built from audited fundamentals. The current price: ₹3.20.
What is the quality score of 530665?
Zenith Healthcare Limited has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zenith Healthcare Limited (530665)?
Our model-based price target is the fair value of ₹1.88 (as of Nov 17, 2026) from 8 valuation models. Cautious scenario ₹1.88, optimistic scenario ₹2.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Zenith Healthcare Limited stock forecast for 2026?
Our models put fair value at ₹1.88, about 41% lower versus a price of ₹3.20 (overvalued). Cautious scenario ₹1.88, optimistic scenario ₹2.82. The calculation is refreshed regularly with new filings.
What is the revenue of Zenith Healthcare Limited (530665)?
Zenith Healthcare Limited reported trailing-twelve-month revenue of about ₹146M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Zenith Healthcare Limited (530665)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zenith Healthcare Limited it is ₹1.88 per share (as of Nov 17, 2026), against a price of ₹3.20. It is the blended result of 8 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Zenith Healthcare Limited stock overvalued or undervalued in 2026?
As of Nov 17, 2026, 530665 trades above its calculated fair value: price ₹3.20, fair value ₹1.88, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 530665?
No. The price is what the market pays today (₹3.20); the fair value is what the company's own numbers justify (₹1.88). For Zenith Healthcare Limited the two are ₹1.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zenith Healthcare Limited worth?
The market values Zenith Healthcare Limited at about ₹247M (market capitalisation, as of Nov 17, 2026). Per share that is ₹3.20; our models calculate a fair value of ₹1.88 per share.
What do the bullish and bearish scenarios say about 530665?
Our models span a range for Zenith Healthcare Limited: cautious scenario ₹1.88, base ₹1.88, optimistic ₹2.82 per share (as of Nov 17, 2026, price ₹3.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 530665?
Zenith Healthcare Limited trades at a price-to-earnings ratio of 30.1 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1.88 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2018 to 2026), reported earnings: 108.5. Other multiples: P/B 3.3, P/S 1.7, EV/EBITDA 21.1.
How solid is the balance sheet of Zenith Healthcare Limited (530665)?
Balance-sheet figures for Zenith Healthcare Limited (as of Nov 17, 2026): return on equity 15.7%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 530665 from its 52-week high?
Zenith Healthcare Limited trades at ₹3.20, about 18% below its 52-week high of ₹3.89 and 32% above the low of ₹2.42 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1.88 is for.
Which stocks are comparable to Zenith Healthcare Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zenith Healthcare Limited stock attractive at the current price?
The data as of Nov 17, 2026: price ₹3.20, calculated fair value ₹1.88 (−41%), Quality Score 52/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 530665 calculated?
We run Zenith Healthcare Limited through 8 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹1.88 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Zenith Healthcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zenith Healthcare Limited (530665)?
The closing price on Nov 16, 2026 was ₹3.20. Our model-based fair value is ₹1.88, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zenith Healthcare Limited right now?
The price sits above even our optimistic bull case (₹2.82). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Zenith Healthcare Limited

How large is the market capitalisation of Zenith Healthcare Limited (530665)?
The market capitalisation of Zenith Healthcare Limited is ₹247M (≈ $2.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zenith Healthcare Limited (530665)?
The price-to-sales ratio of Zenith Healthcare Limited is 1.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zenith Healthcare Limited (530665)?
Earnings per share at Zenith Healthcare Limited are ₹0.1700 (price ÷ EPS = P/E 30.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zenith Healthcare Limited (530665)?
The net margin of Zenith Healthcare Limited is 6.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zenith Healthcare Limited (530665)?
The return on equity (ROE) of Zenith Healthcare Limited is 15.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zenith Healthcare Limited (530665)?
On an EBIT basis the return on assets of Zenith Healthcare Limited is −1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zenith Healthcare Limited (530665)?
The operating margin of Zenith Healthcare Limited is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zenith Healthcare Limited (530665)?
Revenue at Zenith Healthcare Limited is growing 51.6% versus a year earlier (3y avg −7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zenith Healthcare Limited (530665)?
Earnings per share at Zenith Healthcare Limited are growing 856% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zenith Healthcare Limited (530665) generate?
The free cash flow of Zenith Healthcare Limited is −₹9.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Zenith Healthcare Limited in the live analysis

One click puts Zenith Healthcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.